HF
LABT

HRT Financial’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History

HRT Financial’s Portfolio LABT Stock Details LABT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Buy
+44,782
New +$768K ﹤0.01% 3522

Other funds holding LABT

MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HRT Financial's LABT Position: Q2 2026 in Review

HRT Financial opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q2 2026: 44,782 shares worth $140K. The stake represents ﹤0.01% of the portfolio and ranks #3522 among its holdings.

6 funds tracked by Wall St. Rank hold LABT as of Q2 2026.

  • HRT Financial held 44,782 shares of Lakewood-Amedex Biotherapeutics worth $140K as of Q2 2026.
  • Lakewood-Amedex Biotherapeutics was a new HRT Financial position in Q2 2026.
  • Lakewood-Amedex Biotherapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3522 holding.
  • 6 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.